AYURVEDIC APPROACH OF ALLERGIC CONJUNCTIVITIS (VATAJA ABHISHYANDA)

2021 ◽  
Vol 9 (5) ◽  
pp. 988-994
Author(s):  
Manisha Rajput ◽  
Sukhdev Singh ◽  
Sanjeev Kumar Sharma ◽  
Yogitha Bali M.R
Keyword(s):  
Adverse Effects ◽  
Allergic Conjunctivitis ◽  
Age Groups ◽  
Modern Medicine ◽  
Ayurvedic Medicine ◽  
Eye Drops ◽  
Root Cause ◽  
Effective Interventions ◽  
Eye Disorders ◽  
Chronic Course

Allergic conjunctivitis is one of the most common eye disorders that affect people of all age groups and can be correlated to Vatajaabhishyanda (Allerghic Conjunctivitis) in Ayurvedic medicine based on their signs and symp- toms. Abhishyanda (Conjunctivitis) is the root cause for most of the eye disorders and must be treated early with effective interventions or it might lead to severe complications and would be very perplexing to save the eyesight. If Abhishyanda (Conjunctivitis) takes a chronic course, it may lead to dreadful complications making the disease unmanageable. In Modern medicine, this is managed with the administration of eye drops and anti-Allergic medi- cines associated that are associated with some adverse effects. Ayurvedic management of Allergic conjunctivitis has shown some effective results in overcoming the ailment with no such effects and non-recurrence. Hence here an effort has been made to elucidate about Vatajaabhishyanda and its management that is outlined in Ayurvedic classics. Keywords: Vatajaabhishyanda, Allergic conjunctivitis, Ayurveda, Shalakya Tantra

scholarly journals EFFICACY OF ASCHYOTANA IN THE MANAGEMENT OF VATAJA ABHISHYANDA (ALLERGIC CONJUNCTIVITIS): AN OBSERVATIONAL STUDY

AYUSHDHARA ◽  
2020 ◽  
pp. 2636-2642
Author(s):  
Manisha Rajput ◽  
Sukhdev Singh ◽  
Sanjeev Kumar Sharma ◽  
Yogitha Bali M.R
Keyword(s):  
Allergic Rhinitis ◽  
Observational Study ◽  
Random Sampling ◽  
Allergic Conjunctivitis ◽  
Age Groups ◽  
Himachal Pradesh ◽  
Burning Sensation ◽  
Eye Drops ◽  
Eligibility Criteria ◽  
The People

Background: Inflammation of the conjunctiva due to allergy is known as allergic conjunctiva. It is also seen in the people suffering from allergic rhinitis and is affected by all age groups at least once in their lifetime. But older population and children are more prone for allergic conjunctivitis. Objectives: To evaluate the effect of Aschyotana karma or the therapy with Bilvadi eye drops in the management of Vataja abhishyanda (allergic conjunctivitis). Design: This was an observational study with random sampling. Forty subjects who fulfilled the eligibility criteria were included for the study. Patients with complaints of Allergic Conjunctivitis were selected from OPD of Department of Shalakya Tantra (Netra-Roga), R.G.G.P.G. Ayu. Hospital Paprola, Himachal Pradesh. These patients were administered Bilvadi aschyotana 2 eye drops 4to 5 times for 15 days and were assessed for itching, redness, burning sensation and photophobia before the treatment, on the 3rd day, once in a week and after the treatment.  Results: Aschyotana with Bilvadi eye drops in Vataja abhishyanda provided significant relief in itching 70.09%, redness 41.7%, burning sensation 47.6% and photophobia 53.3%.  

A Survey of Neonatal Nurses on Mydriatic Regimens Used in Neonatal Retinopathy of Prematurity Eye Examinations

2021 ◽  
Author(s):  
Lisa Kremer ◽  
David Reith ◽  
Natalie J. Medlicott ◽  
Mary J. Sime ◽  
Liza Edmonds ◽  
...  
Keyword(s):  
New Zealand ◽  
Adverse Effects ◽  
Retinopathy Of Prematurity ◽  
Adverse Drug Events ◽  
Preterm Neonates ◽  
Eye Drops ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Aotearoa New Zealand ◽  
Adult Dose

Objective This study was aimed to determine mydriatic regimen(s) used in neonatal units in Aotearoa New Zealand (NZ) and Australia and to estimate the frequency of adverse drug events following mydriatic administration in preterm neonates. Study Design A cross-sectional survey was sent to neonatal nursing staff listed in the Australian and New Zealand Neonatal Network contact list. Participants were asked to state what mydriatic regimen they use, and to estimate the frequency of adverse drug events when eye drops were administered for retinopathy of prematurity eye examinations (ROPEE). Results Thirteen different mydriatic regimens were identified; phenylephrine 2.5% and cyclopentolate 0.5% (1 standard drop of each) was the most commonly used regimen. Two of the regimens exceeded adult doses and five regimens included a mydriatic that is equivalent to an adult dose. Following mydriatic instillation, the three most common adverse effects were apnea, tachycardia, and periorbital pallor. Conclusion Low-concentration single-microdrop regimens are currently in use and resulting in successful ROPEE, yet doses exceeding adult doses are in use throughout Aotearoa NZ and Australian units. We know from this dataset that neonates are experiencing unwanted and potentially preventable, adverse effects associated with mydriatics, and every effort should be made to minimize this risk. Key Points

scholarly journals A prospective study of efficacy and safety of olopatadine versus azelastine in allergic conjunctivitis at a tertiary care hospital

2017 ◽  
Vol 6 (8) ◽  
pp. 1948 ◽  
Author(s):  
Jayanthi C. R. ◽  
Nanthini R. ◽  
. Vijayalakshmi
Keyword(s):  
Mast Cell ◽  
Adverse Events ◽  
Allergic Conjunctivitis ◽  
Tertiary Care ◽  
Signs And Symptoms ◽  
Eye Drops ◽  
Care Hospital ◽  
Efficacy And Safety ◽  
H1 Receptor ◽  
Olopatadine Hydrochloride

Background: Allergic conjunctivitis, an ocular surface inflammatory disease with significant social and economic impact affects approximately 25% of the general population. H1 receptor blockers, mast cell stabilizers and drugs that block cytokine and prostaglandin formation form the treatment armamentarium. Olopatadine hydrochloride and Azelastine hydrochloride are dual-acting selective H1 receptor antagonist with mast-cell stabilizing property. This study was undertaken to assess the efficacy and safety of olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% in allergic conjunctivitis amongst Indians.Methods: After obtaining Institutional Ethics Committee approval and written informed consent, 120 patients diagnosed with allergic conjunctivitis fulfilling the inclusion/exclusion criteria were enrolled in the study. Study was done from April 2014 to June 2015 at Minto eye hospital. Study subjects were treated with olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% eye drops BD for 15 days. Ocular symptoms, instead of and signs and adverse events, if any were recorded on the day 8 and day 15 follow up visits.Results: At the end of the study period, the reduction in the ocular itching score from baseline was higher in the olopatadine group compared to the azelastine group (p<0.002). Similarly, the scores of ocular congestion (p<0.008), foreign body sensation (p<0.009), tearing (p<0.001), erythema (p<0.002) and chemosis (p<0.015) also showed larger reduction in the olopatadine treated patients. The common adverse events encountered in both the groups were stinging after instillation, burning, bitter taste and headache.Conclusions: In allergic conjunctivitis, both olopatadine and azelastine were found to be effective in relieving ocular signs and symptoms, but olopatadine was found to be superior in terms of efficacy, safety and tolerability with minimal side effects.

Ethics in Clinical Studies: The Dilemma of very Young and Old

2021 ◽  
Vol 3 (2) ◽  
Author(s):  
Avisek Dutta ◽  
Avisek Dutta ◽  
Avisek Dutta
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Human Physiology ◽  
Informed Consent ◽  
Adverse Effects ◽  
Age Groups ◽  
The Elderly ◽  
Infantile Spasms ◽  
Care Givers ◽  
Improve Health

The objectives of the research are to percolate knowledge which can improve health and improve understanding of human physiology. Pervasive exclusion of children and elderly in clinical trials as is happening today is not justified. Children have different physiology and pharmacology from adults; often adverse effects are also different and specific. Diseases like neonatal hyperbilirubinemia, infantile spasms are very age specific. Elderly too, have age specific issues like dementias, malignancies, weakened systems and polypharmacy that make them a special cohort. Clinical trials in these age groups are essential so as to gather comprehensive data about a medication across all age groups. Informed consent is a challenge in both these groups. It can be remedied by obtaining consent from parents, or legally acceptable representative in case of children and care givers and/or LARs in case of the elderly. Oral assent from 7 to 11 years, and written assent from 12 to 18 years and in the elderly, along with consent from the LAR, parents, care givers as the case may be, forms the bedrock of good clinical trial ethics.

E

2020 ◽  
pp. 275-307
Author(s):  
Sean Ainsworth
Keyword(s):  
Adverse Effects ◽  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Recombinant Human Erythropoietin ◽  
Eye Drops ◽  
Enzyme Replacement ◽  
Maternal Treatment ◽  
Human Erythropoietin

This chapter presents information on neonatal drugs that begin with E, including use, pharmacology, adverse effects, fetal and infant implications of maternal treatment, treatment, and supply of Enemas, laxatives, and suppositories, Enoxaparin, Enzyme replacement therapy, Epoetin (recombinant human erythropoietin = rEPO), Epoprostenol and other prostanoids (iloprost and teoprostinil), Erythromycin, Esomeprazole, Ethambutol, and Eye drops (and ointments)

From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer

2006 ◽  
Vol 10 (1) ◽  
pp. 87-118 ◽  
Author(s):  
Bharat B Aggarwal ◽  
Haruyo Ichikawa ◽  
Prachi Garodia ◽  
Priya Weerasinghe ◽  
Gautam Sethi ◽  
...  
Keyword(s):  
Therapeutic Targets ◽  
Modern Medicine ◽  
Ayurvedic Medicine

Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

2019 ◽  
Vol 26 (3) ◽  
pp. 655-665 ◽  
Author(s):  
Yusuke Noguchi ◽  
Yugo Kawashima ◽  
Megumi Maruyama ◽  
Hiroko Kawara ◽  
Yoko Tokuyama ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Confidence Interval ◽  
Odds Ratio ◽  
Case Control Study ◽  
Japanese Patients ◽  
Case Control ◽  
Current Status ◽  
Eye Drops ◽  
Eye Disorders ◽  
Control Study

Purpose Docetaxel is known to cause eye disorders. In this study, current status of eye disorders caused by docetaxel administration every 3 weeks in Japanese patients was examined. Methods This case-control study targeted patients who were newly administered docetaxel at the Kyoto Okamoto Memorial Hospital between 1 July 2015 and 30 June 2018. Eye disorder occurrence was defined as an event in which the pharmacist confirmed the symptoms in a patient interview and the ophthalmologist diagnosed the disorder. Results Of the 89 subjects, 7 (7.9%) had eye disorders. The symptoms were watering eyes (7.9%), a stye and eye discharge (2.2% each), corneal and conjunctival disorder, visual acuity reduction, and blepharedema (1.1% each). Four patients who presented with watering eyes, eye discharge, or corneal and conjunctival disorder showed improvement with the use of eye drops such as artificial tears. Two patients who presented with a stye showed improvement with the use of oral cefcapene. One patient with mild symptoms showed spontaneous improvement. However, one patient had irreversible visual acuity reduction. The multivariate logistic regression analysis revealed that a cumulative docetaxel dose of ≥300 mg/m2 (odds ratio: 15.50, 95% confidence interval: 1.37–175.00, p = 0.027) and concomitant cyclophosphamide use (odds ratio: 13.20, 95% confidence interval: 1.13–153.00, p = 0.039) were significant risk factors associated with eye disorders. Conclusion In conclusion, it was determined that docetaxel-related eye disorders might be influenced by the cumulative dose of docetaxel and concomitant cyclophosphamide use. In addition, relatively mild symptoms improved with medication.

Sign in / Sign up

Export Citation Format

Share Document